We histologically characterized plasma cell niches in the CNS and identified follicle-like structures containing B cells close to vessels and PDGFRb+ cells forming a reticular network expanding to the parenchyma. To find out if these structures could provide sufficient homing locations which support plasma cells to become long-lived, we performed 5-ethynyl-2′-deoxyuridine (EdU)-pulse experiments. During pulse, EdU is incorporated by dividing cells like plasma blasts. The detection of EdU-positive cells up to seven weeks after pulse suggests that niches in the CNS can favor survival of plasma cells. We then further analyzed the migration of plasma blasts to the CNS. Since the sphingosine-1-phosphate analogon FTY720 (fingolimod) is known to suppress immune cell trafficking, we performed EAE experiments under accompanying treatment with the drug. FTY720-treated animals were resistant to EAE in contrast to control animals. Immunofluorescent histological findings confirmed that no immune cell infiltration took place in FTY720-treated animals and the protective effect of FTY720 was not due to retention of immune cells in spleen, lymph nodes or bone marrow, as proved by quantitative FACS analysis. Control mice displayed massive immune cell infiltration in the perivascular space and parenchyma of the CNS, some evidently of long-lived phenotype. These results can be useful to evaluate the therapeutic potential of targeting plasma cells in chronic neuroinflammation. The detection of antibodies to aquaporin-4 (AQP4) has diagnostic relevance for patients with clinical features of neuromyelitis optica spectrum disorders (NMOSD). Different AQP4 diagnostic assay methodologies are used in diagnostic centres within Europe. We compared the sensitivity and specificity of 21 different assays performed in 15 European centres. 101 coded samples from patients with NMOSD (66 designated AQP4 seropositive) and 93 from neurological/immune/healthy controls were distributed and the results independently tabulated before analysis.
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Overall the assays ranged in sensitivity from 51.4% to 100% with a median of 92.4%. The live cell based assays (CBAs), run in 3 centres, had a median sensitivity of 100% (range: 98.5%-100%); the commercial fixed (fCBA; Euroimmun) had a median sensitivity of 92.4%, either measured by the company or by 7 other groups. Greater variation in sensitivities, 83-94%, was seen at the other centres who used fCBA, indirect immunohistochemistry (3 centres; median sensitivity 51-98%) or cytometry (4 centres; 69.7% to 100%), and the ELISA, runs at a single centre, was least sensitive (83%). The specificity of the assays ranged from 86.9% to 100% with the commercial fixed CBA the most specific. There was significant variation between different centres using immunohistochemistry or flow cytometry.
Assays based on recombinant protein expressed in cells and scored by visual assessment of fluorescence, provide the most consistent results with high sensitivity and specificity. Flow cytometry and tissue based assays at individual centres can be as sensitive and specific, but appear more susceptible to variations between centres. There are now a number of neuronal antigenic targets for the identification of patients with autoimmune CNS disorders, and it will be important to establish appropriate quality assurance schemes for the assays. 
